LYEL vs VIR
LYEL: Late-stage clinical cell therapy company engineering next-generation dual-targeting CD19/CD20 CAR T-cell therapies for blood cancers and solid tumors, with a lead program in pivotal trials and an in-house manufacturing facility. VIR: Vir Biotechnology develops novel immunology-driven therapeutics targeting infectious diseases and cancer using proprietary T-cell engagement and masking technologies.
Side-by-side fundamentals
| Metric | LYEL | VIR | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $12.96 | $8.90 | |
| Market cap as of 2026-07-31 | $302M | $1.5B | |
| Net margin as of 2026-07-31 | -794858.1% | -638.9% | VIR higher |
| Gross margin as of 2026-07-31 | n/a | +100.0% | |
| Operating margin as of 2026-07-31 | -823341.9% | -699.2% | VIR higher |
| ROE as of 2026-07-31 | -85.7% | -49.3% | VIR higher |
| ROA as of 2026-07-31 | -66.4% | -38.7% | VIR higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-31 | -52.3% | -7.6% | VIR higher |
| Revenue CAGR (3y) SEC XBRL | -92.5% | -65.1% | VIR higher |
| Beta as of 2026-07-31 | -0.04 | 1.53 | |
| 1-year return as of 2026-07-27 close | +4.3% | +69.8% | VIR higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.